TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors
Brief Summary: This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.


Options:
A: Inclusion Criteria:

* RA, symptom duration \< 12 months

Exclusion Criteria:

* Contraindication to any of the trial medications
B: Inclusion Criteria:

* The subject has a history of inadequate response to at least 1, but no more than 4, of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)

Exclusion Criteria:

* Current Therapy With Any DMARD Or Biologic
C: Inclusion Criteria:

* Diagnosis of RA according to the American College of Rheumatology criteria for at least 3 months prior to screening
* Have active Rheumatoid Arthritis at the time of screening and at baseline, as defined by 6 or more swollen joints and 6 or more tender joints and additional laboratory criteria

Exclusion Criteria:

* Have other inflammatory diseases, including but not limited to ankylosing spondylitis, systemic lupus erythematosus, Lyme disease
* Received disease-modifying antirheumatic drugs (\[DMARDs\] eg, D penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold, interleukin \[IL\]-1 receptor antagonist \[anakinra\], azathioprine, sulphasalazine, agents other than MTX) within 4 weeks prior to the first study dose
D: Inclusion Criteria:

* Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate who have inadequate response to Tumor Necrosis Factor (TNF) inhibitors.

Exclusion Criteria:

* Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effectiveness of Dance on Patients With Fibromyalgia
Brief Summary: The aim of the present study is to assess the effectiveness of belly dance as a treatment for pain and improving the quality of life of patients with fibromyalgia.

Eighty female patients with fibromyalgia between 18 to 65 years were randomly allocated to a dance group (n=40) and control group (n=40). Patients in the dance group underwent 16 weeks of belly dance twice a week, while the patients in the control group remained on a waiting list. Patients were evaluated with regard to pain (Visual Analogue Scale), function (6 minute walk test), quality of life (Fibromyalgia Impact Questionnaire and SF-36), depression (Beck Inventory), anxiety (State-Trait Anxiety Inventory) and self-image (Body Dysmorphic Disorder Examination) questionnaire. Evaluations were carried out at baseline, after 16 weeks and after 32 weeks.


Options:
A: Inclusion Criteria:

* Clinical diagnosis of Fibromyalgia according to the criteria of the American College of Rheumatology;

  * Clinical diagnosis of TMD by the RDC questionnaire (annex I);
  * Cognitive Level enough to understand the procedures and follow the guidelines that will be passed;
  * People who use drugs corresponding to Fibromyalgia (FM), antidepressant;
  * Class I of angle
  * Consent to participate in the study and sign the consent form post information.

Exclusion Criteria:

* With psychiatric disorders;
* Cognitive Changes;
* People who perform some exercise;
* People who carry out orthodontic treatment;
* Systemic diseases;
* Persons under the age of 35 and more than 58 years.
B: Inclusion Criteria:

* Women with Fibromyalgia, interested in exercise twice a week

Exclusion Criteria:

* Other severe diseases
C: Inclusion Criteria:

* classification of fibromyalgia based on the criteria of the American College of Rheumatology
* female gender
* aged between 18 and 65 years

Exclusion Criteria:

* not having altered treatment in previous three years
* having signed a term of informed consent
* patients with other rheumatic diseases, painful osteoarticular conditions, uncontrolled cardiopulmonary disease, diseases of the lower limbs or uncontrolled diabetes were excluded
D: Inclusion Criteria: ACR 1990 criteria for fibromyalgia -

Exclusion Criteria: Other dominating pain condition, severe disease preventing from participating in physical exercise

-

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effectiveness of Dance on Patients With Fibromyalgia
Brief Summary: The aim of the present study is to assess the effectiveness of belly dance as a treatment for pain and improving the quality of life of patients with fibromyalgia.

Eighty female patients with fibromyalgia between 18 to 65 years were randomly allocated to a dance group (n=40) and control group (n=40). Patients in the dance group underwent 16 weeks of belly dance twice a week, while the patients in the control group remained on a waiting list. Patients were evaluated with regard to pain (Visual Analogue Scale), function (6 minute walk test), quality of life (Fibromyalgia Impact Questionnaire and SF-36), depression (Beck Inventory), anxiety (State-Trait Anxiety Inventory) and self-image (Body Dysmorphic Disorder Examination) questionnaire. Evaluations were carried out at baseline, after 16 weeks and after 32 weeks.


Options:
A: Inclusion Criteria:

* Criteria diagnosis according ACR 1990
* Wash-out of medication specific for fibromyalgia for 1 month
* Only paracetamol 750mg will be allowed during the period of study.

Exclusion Criteria:

* Alterations that against indicate the practical one of physical activity evaluated previously in clinical and rheumatology evaluation
B: Inclusion Criteria:

* Women with Fibromyalgia, interested in exercise twice a week

Exclusion Criteria:

* Other severe diseases
C: Inclusion Criteria:

* classification of fibromyalgia based on the criteria of the American College of Rheumatology
* female gender
* aged between 18 and 65 years

Exclusion Criteria:

* not having altered treatment in previous three years
* having signed a term of informed consent
* patients with other rheumatic diseases, painful osteoarticular conditions, uncontrolled cardiopulmonary disease, diseases of the lower limbs or uncontrolled diabetes were excluded
D: Inclusion Criteria: ACR 1990 criteria for fibromyalgia -

Exclusion Criteria: Other dominating pain condition, severe disease preventing from participating in physical exercise

-

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients
Brief Summary: This study tests the hypothesis that controlled ovarian stimulation impairs endometrial receptivity in high responders.


Options:
A: Inclusion Criteria:

* 1st, 2nd or 3rd cycle of PGD in which embryo transfer was performed
* Indications for PGD: monogenic indications and X-linked disorders with a 25-50% risk of transmission and that are not associated with reduced ovarian response
* Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
* Regular menstrual cycles of 21-35 days, presumed to be ovulatory.

Exclusion Criteria:

* POLYCYSTIC OVARIAN SYNDROME (Rotterdam criteria \*)

  \* At least two of the following three features: (i) Oligo- and/or anovulation (ii) Clinical and/or biochemical signs of hyperandrogenism (iii) Polycystic ovaries and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumours, Cushing's syndrome)
* Poor responders (Bologna criteria \*\*)

  \* \* At least two of the following three features: (i) Advanced maternal age (≥40 years) or any other risk factor for poor ovarian response (POR); (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. antral follicle count (AFC) 5-7 follicles, or anti-Mullerian hormone (AMH) 0.5-1.1 ng/ml).
* Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)
* anticipated high response: AMH \>5.0 ng/ml or AFC \>20
* Endometriosis ≥ grade 3
* Age \> 40 years and 364 days
B: Inclusion Criteria:

* female patients undergoing IVF procedures
* age less than 39 years

Exclusion Criteria:

* less than 4 fertilized eggs in day 1 after IVF
C: Inclusion Criteria:

1. Female patient 18 to 40 years of age seeking their first IVF treatment.
2. Cycle day 3 FSH less than 10.0 IU/l.
3. More than 15 antral follicles observed on ultrasound.

Exclusion Criteria:

1. Failure to follow the protocol.
2. Embryo biopsy.
3. Any prior IVF cycle(s).
D: Inclusion Criteria:

* AMH (Anti-Müllerian hormone) \> 6.28 pmol/L (Roche Elecsys assay)
* Female age 18 years to less than 40 years
* 1, 2 or 3 IVF/ICSI cycle with oocyte aspiration
* Regular menstrual cycle between 24 and 35 days
* BMI between 18 and 35
* Two ovaries
* Can and will sign informed consent

Exclusion Criteria:

* Women who do not fulfil the inclusion criteria
* Endometriosis stage III to IV
* Ovarian cysts with diameter \> 30 mm at day of start of stimulation
* Submucosal fibroids
* Women with severe co-morbidity (IDDM, NIDDM, gastrointestinal, cardiovascular, pulmonary, liver or kidney disease)
* Dysregulation of thyroid disease
* Not danish or English speaking women
* Contraindications or allergies to use of Gonadotrophins or GnRH antagonists
* TESA (testicular sperm aspiration)
* OD (oocyte donation)
* Previous inclusion in the study

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients
Brief Summary: This study tests the hypothesis that controlled ovarian stimulation impairs endometrial receptivity in high responders.


Options:
A: Inclusion Criteria:

* Undergoing In-vitro fertilization (IVF) treatment
* Number of previous failed embryo transfers ≤ 2
* Permanent living in Viet Nam
* Ovarian hyperstimulation with Gonadotropin releasing hormone (GnRH) antagonist protocol
* Eligible for embryo transfer (ET) on day 3
* Having at least one top-quality embryo on day 3.
* Number of embryos transferred ≤ 2
* Willing to participate in the study
* Not to participate in another IVF study at the same time

Exclusion Criteria:

* women with polycystic ovary syndrome
* In vitro maturation (IVM) cycles
* Oocyte donation cycles
* Using GnRH agonist for triggering
B: Inclusion Criteria:

1. Female patient 18 to 40 years of age seeking their first IVF treatment.
2. Cycle day 3 FSH less than 10.0 IU/l.
3. More than 15 antral follicles observed on ultrasound.

Exclusion Criteria:

1. Failure to follow the protocol.
2. Embryo biopsy.
3. Any prior IVF cycle(s).
C: Inclusion Criteria:

* Female patient 18 to 40 years of age seeking their first IVF treatment.
* Cycle day 3 FSH less than 10.0 IU/l.
* 8 to 15 antral follicles observed on ultrasound.

Exclusion Criteria:

* Failure to follow the protocol.
* Embryo biopsy.
* Any prior IVF cycle(s).
D: Inclusion Criteria:

* First or second IVF/ICSI cycle
* High response to ovarian stimulation (defined as presence of ≥18 follicles of ≥11 mm on the day of GnRH triggering)
* GnRH antagonist down-regulation
* Signed informed consent
* Patients can be included only once in the trial
* Planned replacement of 1 or 2 blastocysts

Exclusion Criteria:

* Other known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis)
* Oocyte/embryos donation acceptors
* Embryos planned to undergo preimplantation genetic diagnosis/screening
* Body mass index ≥35 or ≤18
* Women who have previously enrolled in the trial
* Those unable to comprehend the investigational nature of the proposed study

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients
Brief Summary: This study tests the hypothesis that controlled ovarian stimulation impairs endometrial receptivity in high responders.


Options:
A: Inclusion Criteria:

* Women diagnosed as PCOS according to Chinese PCOS diagnosis criteria;
* Women who have ≥1 years history of infertility;
* Women aged ≥20 and \<35 years old;
* Women with body weight ≥40kg;
* Women who have at least one of the following indications for IVF or ICSI:

  1. Ovulation dysfunction and failed to become pregnant from ovulation induction treatment;
  2. Tubal factors: unilateral or bilateral tubal obstruction, adhesion, unilateral or bilateral Salpingectomy or tubal ligation;
  3. Male factors: oligoasthenozoospermia, obstructive azoospermia;
* Women who are undergoing their first cycle of IVF or ICSI;
* Women who retrieved oocytes number \> 3;
* Women who are capable of giving informed consent.

Exclusion Criteria:

* Women who underwent unilateral ovariectomy;
* Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion;
* Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
* Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times;
* Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy;
* Women who has developed severe OHSS before oocyte pick-up day;
* Women with retrieved oocytes number ≤3;
* Women who are unable to comply with the study procedures.
B: Inclusion Criteria:

* Participant must have provided written informed consent for the trial.
* Participant must have cryopreserved embryo(s) in trial P06029 (NCT01144416) of which at least one embryo is thawed for use in a subsequent FTET cycle.
C: Inclusion Criteria:

* age \< 38
* normal day 3 FSH
* classified as high risk for OHSS
* has ≥ 15 follicles with a mean diameter ≥ 12 mm per each ovary
* E2 levels on the day of hCG administration \> 3000 pg/mL
* undergoing her first assisted reproduction treatment cycle

Exclusion Criteria:

* who does not have good-quality embryos appropriate for cryopreservation
D: Inclusion Criteria:

1. Female patient 18 to 40 years of age seeking their first IVF treatment.
2. Cycle day 3 FSH less than 10.0 IU/l.
3. More than 15 antral follicles observed on ultrasound.

Exclusion Criteria:

1. Failure to follow the protocol.
2. Embryo biopsy.
3. Any prior IVF cycle(s).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients
Brief Summary: This study tests the hypothesis that controlled ovarian stimulation impairs endometrial receptivity in normal responders.


Options:
A: Inclusion Criteria:

* Female patient 18 to 40 years of age seeking their first IVF treatment.
* Cycle day 3 FSH less than 10.0 IU/l.
* 8 to 15 antral follicles observed on ultrasound.

Exclusion Criteria:

* Failure to follow the protocol.
* Embryo biopsy.
* Any prior IVF cycle(s).
B: Inclusion Criteria:

* Women diagnosed as PCOS according to Chinese PCOS diagnosis criteria;
* Women who have ≥1 years history of infertility;
* Women aged ≥20 and \<35 years old;
* Women with body weight ≥40kg;
* Women who have at least one of the following indications for IVF or ICSI:

  1. Ovulation dysfunction and failed to become pregnant from ovulation induction treatment;
  2. Tubal factors: unilateral or bilateral tubal obstruction, adhesion, unilateral or bilateral Salpingectomy or tubal ligation;
  3. Male factors: oligoasthenozoospermia, obstructive azoospermia;
* Women who are undergoing their first cycle of IVF or ICSI;
* Women who retrieved oocytes number \> 3;
* Women who are capable of giving informed consent.

Exclusion Criteria:

* Women who underwent unilateral ovariectomy;
* Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion;
* Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
* Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times;
* Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy;
* Women who has developed severe OHSS before oocyte pick-up day;
* Women with retrieved oocytes number ≤3;
* Women who are unable to comply with the study procedures.
C: Inclusion Criteria:

* female patients undergoing IVF procedures
* age less than 39 years

Exclusion Criteria:

* less than 4 fertilized eggs in day 1 after IVF
D: Inclusion Criteria:

* AMH (Anti-Müllerian hormone) \> 6.28 pmol/L (Roche Elecsys assay)
* Female age 18 years to less than 40 years
* 1, 2 or 3 IVF/ICSI cycle with oocyte aspiration
* Regular menstrual cycle between 24 and 35 days
* BMI between 18 and 35
* Two ovaries
* Can and will sign informed consent

Exclusion Criteria:

* Women who do not fulfil the inclusion criteria
* Endometriosis stage III to IV
* Ovarian cysts with diameter \> 30 mm at day of start of stimulation
* Submucosal fibroids
* Women with severe co-morbidity (IDDM, NIDDM, gastrointestinal, cardiovascular, pulmonary, liver or kidney disease)
* Dysregulation of thyroid disease
* Not danish or English speaking women
* Contraindications or allergies to use of Gonadotrophins or GnRH antagonists
* TESA (testicular sperm aspiration)
* OD (oocyte donation)
* Previous inclusion in the study

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients
Brief Summary: This study tests the hypothesis that controlled ovarian stimulation impairs endometrial receptivity in normal responders.


Options:
A: Inclusion Criteria:

* First or second IVF/ICSI cycle
* High response to ovarian stimulation (defined as presence of ≥18 follicles of ≥11 mm on the day of GnRH triggering)
* GnRH antagonist down-regulation
* Signed informed consent
* Patients can be included only once in the trial
* Planned replacement of 1 or 2 blastocysts

Exclusion Criteria:

* Other known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis)
* Oocyte/embryos donation acceptors
* Embryos planned to undergo preimplantation genetic diagnosis/screening
* Body mass index ≥35 or ≤18
* Women who have previously enrolled in the trial
* Those unable to comprehend the investigational nature of the proposed study
B: Inclusion Criteria:

1. Female patient 18 to 40 years of age seeking their first IVF treatment.
2. Cycle day 3 FSH less than 10.0 IU/l.
3. More than 15 antral follicles observed on ultrasound.

Exclusion Criteria:

1. Failure to follow the protocol.
2. Embryo biopsy.
3. Any prior IVF cycle(s).
C: Inclusion Criteria:

* Participant must have provided written informed consent for the trial.
* Participant must have cryopreserved embryo(s) in trial P06029 (NCT01144416) of which at least one embryo is thawed for use in a subsequent FTET cycle.
D: Inclusion Criteria:

* Female patient 18 to 40 years of age seeking their first IVF treatment.
* Cycle day 3 FSH less than 10.0 IU/l.
* 8 to 15 antral follicles observed on ultrasound.

Exclusion Criteria:

* Failure to follow the protocol.
* Embryo biopsy.
* Any prior IVF cycle(s).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients
Brief Summary: This study tests the hypothesis that controlled ovarian stimulation impairs endometrial receptivity in normal responders.


Options:
A: Inclusion Criteria:

* Women diagnosed as PCOS according to Chinese PCOS diagnosis criteria;
* Women who have ≥1 years history of infertility;
* Women aged ≥20 and \<35 years old;
* Women with body weight ≥40kg;
* Women who have at least one of the following indications for IVF or ICSI:

  1. Ovulation dysfunction and failed to become pregnant from ovulation induction treatment;
  2. Tubal factors: unilateral or bilateral tubal obstruction, adhesion, unilateral or bilateral Salpingectomy or tubal ligation;
  3. Male factors: oligoasthenozoospermia, obstructive azoospermia;
* Women who are undergoing their first cycle of IVF or ICSI;
* Women who retrieved oocytes number \> 3;
* Women who are capable of giving informed consent.

Exclusion Criteria:

* Women who underwent unilateral ovariectomy;
* Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion;
* Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
* Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times;
* Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy;
* Women who has developed severe OHSS before oocyte pick-up day;
* Women with retrieved oocytes number ≤3;
* Women who are unable to comply with the study procedures.
B: Inclusion Criteria:

1. Female patient 18 to 40 years of age seeking their first IVF treatment.
2. Cycle day 3 FSH less than 10.0 IU/l.
3. More than 15 antral follicles observed on ultrasound.

Exclusion Criteria:

1. Failure to follow the protocol.
2. Embryo biopsy.
3. Any prior IVF cycle(s).
C: Inclusion Criteria:

* Female patient 18 to 40 years of age seeking their first IVF treatment.
* Cycle day 3 FSH less than 10.0 IU/l.
* 8 to 15 antral follicles observed on ultrasound.

Exclusion Criteria:

* Failure to follow the protocol.
* Embryo biopsy.
* Any prior IVF cycle(s).
D: Inclusion Criteria:

* Participant must have provided written informed consent for the trial.
* Participant must have cryopreserved embryo(s) in trial P06029 (NCT01144416) of which at least one embryo is thawed for use in a subsequent FTET cycle.

Answer: C